The complement alternative pathway is a powerful arm of the innate immune system that enhances diverse inflammatory responses in the human host. Key to the effects of the alternative pathway is properdin, a serum glycoprotein that can both initiate and positively regulate alternative pathway activity. Properdin is produced by many different leukocyte subsets and circulates as cyclic oligomers of monomeric subunits.
I N V I T E D R E V I E W
Highlighting a difficulty in understanding the complete scope of complement activity is the intricate interplay between regulatory mechanisms that govern complement activation. While most human cells and tissues express membrane-bound regulatory proteins to protect themselves from complement attack, soluble regulatory proteins are recruited to inflammatory sites through interactions with both complement proteins and other ligands defined by the unique composition of the local microenvironment. The soluble complement protein properdin is both a regulator and an initiator of the complement alternative pathway that has potent effects on the level of complement activation. Understanding the complex biology of properdin, however, has proven difficult due to the different sources of properdin used in biochemical studies and its intricate self-associations. Despite these difficulties, experimental data have proven properdin to be both a powerful inflammatory modulator that can greatly enhance tissuedamaging inflammation and a critical promoter of microbial clearance in multiple disease models. Here, we discuss basic principles of, and recent advances in understanding, properdin biology, highlighting areas that require future studies. We progress to describe the interplay between properdin and the negative regulator Factor H, the potential This article is part of a series of reviews covering Preformed Mediators of Defense appearing in Volume 274 of Immunological Reviews.
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of properdin inhibitors in treating human disease with an emphasis on the role of properdin in thromboinflammation, and mention potential consequences of properdin inhibition as evidenced in animal models.
Finally, we briefly elaborate on the utility of using novel strategies to promote properdin activity on the surface of microorganisms. To facilitate discussion, we begin with a condensed review of the complement system, which has been extensively reviewed elsewhere.
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| THE COMPLEMENT SYSTEM
The complement system is a group of soluble blood proteins that rapidly activate in a cascade-like manner to orchestrate inflammatory and immune responses in the human host. Complement activity can be initiated by one of three pathways termed the classical, lectin, and alternative pathways, which all converge at the cleavage of the central protein C3 by an enzymatic complex called the C3 convertase.
C3 cleavage releases the small fragment C3a, and the resulting larger fragment, C3b, can bind covalently to nearby hydroxyl-and aminogroups via an exposed thioester bond. C3b bound to, or in close proximity to, the C3 convertase changes the specificity of the complex, allowing for the cleavage of C5 to C5a and C5b. The terminal pathway activates through a series of conformational changes in complement proteins, initiated by the binding of C5b to C6, followed by sequential binding of C7, C8, and C9 that results in the formation of the membrane attack complex (MAC; C5b-9). 1, 3 The classical and lectin pathways utilize distinct initiation mechanisms that lead to the generation of the same C3 convertase, denoted C4b2b. Classical pathway activation is primarily a result of antibodyantigen interactions that promote the activation of the C1 complex, while the lectin pathway activates in response to recognition of specific carbohydrate patterns by various lectin molecules. The alternative pathway, whose activation mechanism will be discussed below, is unique among the three complement pathways because it can activate without the requirement for specific antigen recognition. 2 Each complement pathway generates the same set of effector molecules to carry out its functions. C3b and its breakdown products iC3b and C3dg tag surfaces for recognition by complement receptors expressed on human cells (CR1, CR2, CR3, CR4, and CRIg). 1 The anaphylatoxins, C3a and C5a, bind to the G-protein-coupled receptors C3a receptor (C3aR) and C5a receptor 1 (C5aR1; CD88), respectively, to promote inflammation and other diverse functions, including cerebellar development, homing of stem cells to the bone marrow, and tissue fibrosis. 4 The MAC is capable of directly forming pores in membranes, leading to direct microbial killing, and sublytic levels of MAC stimulate a variety of proinflammatory responses in human cells, including cell and inflammasome activation. 5 
| The alternative pathway
The alternative pathway continuously activates at a low level in the fluid phase of blood due to spontaneous hydrolysis of the labile thioester bond in C3, in a process known as 'tick-over'. An additional source of C3(H 2 O) may be formed by contact activation on certain cells, such as platelets and artificial surfaces. 6, 7 Upon hydrolysis of its thioester bond, C3 undergoes a conformational change to form C3(H 2 O) and gains the ability to bind Factor B. [8] [9] [10] Factor B in association with C3(H 2 O) is cleaved by Factor D to Ba and Bb, to generate the fluid-phase alternative pathway C3 convertase, C3(H 2 O)Bb.
C3(H 2 O)Bb cleaves additional C3 molecules to C3a and C3b, expos-
ing the labile thioester bond on C3b. 8 The thioester bond is rapidly hydrolyzed by water, and only a small percentage of C3b is able to bind covalently to nearby hydroxyl-and amino-groups on surfaces before hydrolysis. 11 Covalently bound C3b tags surfaces for additional alternative pathway activation. Surface-bound C3b, which is structurally similar to C3(H 2 O), recruits Factor B molecules, which are cleaved by Factor D in an identical manner to that which occurs in the fluid phase. 12 The surface-bound alternative pathway C3 convertase, C3bBb, cleaves more C3 molecules to C3a and C3b, which, if bound covalently to the surface, act as focal points for the assembly of more alternative pathway convertases, effectively amplifying its own 
| Alternative pathway regulation
Its spontaneous nature and its ability to amplify all complement activity make regulation of the alternative pathway a necessity in the human host in order to prevent excessive inflammation and tissue damage. Human cells and tissues are protected from complement attack by various membrane-bound complement regulatory proteins, including CD55, CD59, CD46, and CR1. 1 However, the serum glycoprotein, Factor H (Fig. 3A) , which has been reviewed elsewhere,
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has also proven to be critical to limiting alternative pathway activation on the surface of several cell types, even in the presence of membrane-bound regulators. Factor H is also the primary regulator of the alternative pathway in the fluid phase, preventing complement consumption via uncontrolled alternative pathway activation. 52 Properdin, the focus of this review, has a well-defined role in which it acts as a positive regulator of complement activity by stabilizing the alternative pathway convertase, thus increasing its activity 5-to 10-fold. 53 Properdin stabilizes the convertase by primarily binding C3b, although it makes additional contacts with Factor B and Bb. [54] [55] [56] Properdin binds to C3bB and C3bBb with higher affinity than to C3b alone. 55 Interestingly, properdin has been shown to directly limit Factor H cofactor activity 55, 57 and is predicted to affect Factor H decay accelerating activities via structural data, 54 suggesting that defective Factor H regulation may enhance the positive regulatory functions of properdin. Structural studies by Sun et al. 59 and Alcorlo et al. 54 proposed models for oligomerization. These studies illustrated roles for TSRs 0-1 and 5-6 in mediating contacts at the vertices of properdin oligomers, Ziegler et al. 78 showed that higher levels of properdin were found in the urine of patients with renal disease vs healthy individuals, and
| MOLECULAR STRUCTURE AND CHARACTERISTICS OF PROPERDIN
Corvillo et al. 79 proposed using serum properdin concentrations as a diagnostic marker for a subset of C3 glomerulopathy patients. Studies 
| PROPERDIN AS AN INITIATOR OF ALTERNATIVE PATHWAY ACTIVITY: EVIDENCE AND SETBACKS
When Pillemer first described properdin in 1954, he proposed it acted as an initiator of alternative pathway activity. 80 This theory was later discounted and replaced with the well-established role of properdin Upon repeated freeze-thaw cycles, purified properdin forms nonphysiological aggregates (P n ) that have distinctly different properties from physiological oligomers. First, non-physiological aggregates have 'activated properdin activity', meaning they induce alternative pathway activation in solution leading to complement consumption. 65, 92 Second, non-physiological aggregates bind non-specifically to surfaces, including live Jurkat and Raji cells, 83 Neisseria species, 93 and nonactivated platelets. 31 The physiological oligomers, however, can act as pattern recognition molecules binding selectively to specific surfaces, including zymosan, necrotic Jurkat and Raji cells, 83 Chlamydia pneumoniae, 82 and activated platelets. 31 The arrangement of properdin monomers in non-physiological aggregates (described by Farries as 'large amorphous aggregates') remains unknown, but given the highly positively charged nature of properdin monomers, non-specific ionic interactions with negatively charged anions could account for their robust binding abilities.
Unfractionated properdin isolated from plasma, which contains properdin polymers (P 2 , P 3 , P 4 , and non-physiologicial aggregated P n )
is visualized as approximately 53-kDa monomers in SDS-PAGE under both reduced and non-reduced conditions. Although some studies detect purified properdin at high molecular weights (approximately 220 kDa) in SDS-PAGE, and others have used SDS-PAGE to rule out the presence of aggregates in their properdin preparations, this is inadequate because the polymeric forms (including the non-physiological aggregates) are not visible on an SDS-PAGE 83 due to the non-covalent nature of the polymer associations. The multimers can easily be detected, however, when the same unfractionated properdin preparations are separated by size exclusion or ion exchange chromatography. 83 Interestingly, in a coimmunoprecipitation assay, Pauly et al.
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discovered C3(H 2 O), C3 fragments, clusterin, and immunoglobulins associated with properdin in human serum. Also, C3b 2 -natural IgG complexes have been shown to stimulate complement amplification in a properdin-dependent manner. 95 These associations between properdin and other molecules may account for the properdin that migrates at a high molecular weight in SDS-PAGE in some purified preparations. The nature of the interactions between properdin and these other molecules in human serum, which resist SDS, denaturing, and/or reducing agents, remains to be determined.
Differences have been noted in the binding capabilities of purified properdin vs properdin contained in serum. For instance, purified physiological properdin oligomers bound directly to zymosan in solution, 83 but properdin required C3 activity to bind zymosan in the presence of serum in subsequent studies. 96, 97 Similarly, binding of properdin trimers to thrombin-activated platelets was inhibited in the presence of normal human serum. 31 These results have led to the proposition that properdin binding is regulated in serum by unknown inhibitors. As mentioned above, C3(H 2 O), C3 fragments, clusterin, and immunoglobulins were associated with properdin in human serum.
While the physiological effects of the interactions between these molecules and properdin remain unknown, it is possible that they could account for the qualitative differences in binding observed for purified properdin vs properdin contained in serum. Recent evidence also
indicates that monomeric C-reactive protein (mCRP) inhibits the binding of unfractionated properdin to proximal tubular epithelial cells. 88 Because mCRP is generated and present mainly on cell surfaces or local microenvironments, 98 it is likely that the inhibitory capacity of mCRP may be limited to cell surfaces and not affect properdin activity in normal human serum. The ability of serum to inhibit direct properdin binding can also be influenced by the specific ligands, as Xu et al.
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showed that unfractionated properdin and properdin in either normal human serum or C3-depleted serum bound directly to necrotic cells to approximately the same extent. This adds another layer of complexity to properdin studies, indicating that direct properdin binding is influenced not only by the type of properdin used for the study but also by the specific ligands tested. Inhibitors in serum may fine-tune properdin-initiated functions by limiting direct properdin binding to some, but not all, surfaces.
Because of the ability of neutrophils to secrete properdin from their secondary granules upon stimulation, 76 the concentration of properdin in inflammatory microenvironments is likely higher than the circulating concentration. This suggests that locally produced properdin could bypass regulatory mechanisms that exist in serum thus enabling properdin-initiated alternative pathway activation. Indeed,
Kemper et al. 86 demonstrated that apoptotic T cells bound unfractionated and neutrophil-derived properdin but not properdin from C3-depleted serum. In addition, Saggu et al. 31 demonstrated an ability of neutrophil-derived properdin to bind directly to activated platelets.
Conversely, Harboe et al. 97 showed that neutrophil-derived properdin was incapable of binding directly to solid-phase zymosan, a surface previously shown to directly bind physiological properdin oligomers. 83 The discrepancies between the latter two studies may be due to the different methodologies used to determine properdin binding F I G U R E 6 Properdin functions. Properdin (P) enhances alternative pathway activity in one of two ways: (1) acting as a positive regulator of pre-existing alternative pathway activity or (2) initiating alternative pathway activity. Properdin acts as a positive regulator by stabilizing the alternative pathway C3 and C5 convertases, increasing their activity 5-to 10-fold. As a pattern recognition molecule, properdin binds selectively to specific surfaces upon which it recruits C3b or C3(H 2 O) to initiate alternative pathway activity (solid-phase ELISA 97 vs flow cytometry), 83 or it could be an indication that there are indeed functional differences between physiological properdin oligomers and neutrophil-derived properdin, as discussed in the former section. However, all of these studies utilized purified, unfractionated properdin to investigate binding. Holt et al. noted differences in the binding of physiological ('native') vs non-physiological ('activated') properdin to sulfatides, as well as differences in the GAG preparations that inhibited these interactions. Heparin, dextran sulfate (5000 mw), and chondroitin sulfate C (weakly) impaired the interaction of non-physiological (unfractionated) properdin with sulfatide, but had no effect on physiological properdin binding, 64 suggesting results from studies that utilized unfractionated properdin may not be applicable to the pattern of binding exerted by physiological properdin oligomers. Future studies aimed at determining potential differences between the ability of purified physiological and non-physiological properdin, as well as serum-and neutrophil-derived properdin, to bind GAG preparations could validate results from the aforementioned studies and provide key information about the binding qualities of the different properdin sources.
| PROPERDIN AND THROMBOINFLAMMATION
Within the past decade, there has been a renewed interest in evaluating the role of properdin in disease pathogenesis. This has led to the development of properdin-deficient mice, which have been utilized in murine models of asthma, 103, 104 properdin-initiated alternative pathway activity leads to complete activation of the terminal pathway, as measured by C9 deposited on the platelet surface. Complement activity on platelets is summarized in Fig. 8 .
F I G U R E 7
Main physical contacts governing platelet/granulocyte aggregate interactions. P-selectin initially tethers activated platelets to granulocytes via binding to PSGL-1. This interaction leads to an intracellular signaling cascade that activates and increases the expression of CR3 on granulocytes. CR3 binds multiple ligands on platelets including GPIIb/IIIa through a fibrinogen bridge, GP1bα directly and via a HMWK bridge, ICAM-2, and JAM-3. CD40L and TREM-1L, expressed on activated platelets, enhance granulocyte functions via binding to their granulocyte counter-receptors, CD40 and TREM-1, respectively 
| Properdin and PGA formation
In line with this theory, researchers have elucidated roles for complement in enhancing PGA formation in human whole blood using extracorporeal circuits that simulate coronary artery bypass [151] [152] [153] [154] [155] and ex vivo flow cytometry assays. 145, [156] [157] [158] [159] Rinder et al. 152, 155 demonstrated that PGA formation in an extracorporeal circuit was dependent on C5a-mediated effects, a result that was also seen by Lappegard et al. 151 using a heparin-coated circuit. The latter study also established a role for the alternative pathway in enhancing C5a, by demonstrating the ability of an anti-Factor D antibody to limit PGA formation and upregulation of CR3 on neutrophils. 151 These findings were in agreement with independent studies showing that an antiFactor D 160 or an anti-properdin monoclonal antibody 161 inhibited neutrophil and platelet activation (hallmarks of thromboinflammation) during simulated cardiopulmonary bypass.
Ruef et al. 158 showed that unfractionated properdin could induce platelet/leukocyte aggregate (PLA) formation in human whole blood and significantly enhanced PLA formation in the presence of the weak platelet agonist, ADP in an ex vivo flow cytometry assay. Using a similar system, Blatt et al. 156 recently addressed the role of physiological properdin oligomers in their ability to induce PGA, determining that they enhance PGA formation in the presence of thrombin receptoractivating peptide (TRAP). Each properdin form (dimers, trimers, and tetramers) also sensitized whole blood to PGA formation when added to blood stimulated with a dose of TRAP that induced little to no PGA formation by itself. Properdin tetramers were the most potent oligomer with regard to enhancing PGA formation and alternative pathway activity. These data were in agreement with the high degree of 'native properdin activity' originally ascribed to properdin tetramers by Pangburn 65 and also suggest that high levels of properdin (especially properdin tetramers) in the local microenvironment have the potential to exacerbate thromboinflammation in the presence of relatively weak platelet stimulation. In addition, it was determined that inhibition of endogenous properdin in the blood, using inhibitory antihuman properdin monoclonal antibodies, reduced TRAP-induced PGA
formation by approximately 50% and to the same level as inhibiting all complement activity with compstatin, an inhibitor that prevents C3 cleavage. 156 The overall effect of properdin was attributed to its ability to enhance the generation of C5a leading to the upregulation of CR3 on granulocytes, 156 consistent with the findings from Hamad et al. Hamad et al. 6 also described a novel CR3-C3(H 2 O) interaction between platelets and neutrophils that could mediate stable aggregate formation. Given the ability of properdin to recruit C3(H 2 O) to the platelet surface, 31 it is possible that a dual mechanism for the ability of properdin to enhance PGA formation exists. Properdin may both increase the generation of C5a leading to CR3 upregulation, and directly recruit C3(H 2 O) to the activated platelet surface, providing an additional ligand for CR3 binding. Because inhibition of properdin limits CR3 upregulation on neutrophils (the critical receptor needed for binding to C3(H 2 O) on platelets), 156 it was not possible to discern a potential role for a direct properdin-mediated recruitment of C3(H 2 O) in the whole blood system.
| POTENTIAL FOR PROPERDIN INHIBITORS AS LONG-TERM PROPHYLACTICS FOR PREVENTION OF THROMBOINFLAMMATION
Because increased levels of PGA are associated with many different human diseases, induces a high-affinity conformation for CR3. 168 Based on these previous studies, 6, 145, 156 it is likely that properdin-mediated C5a aids in the transition of CR3 from an intermediate-to high-affinity conformation, increasing the chance that neutrophils stably bind to platelets.
This may help to explain why inhibition of properdin or C5a only limits, rather than completely abrogates, TRAP-mediated PGA formation.
The partial effect of complement inhibition on TRAP-mediated PGA formation leads to the possibility that complement activity could be the force that increases granulocyte accumulation at thromboinflammatory sites to a level that becomes pathologic, rather than homeostatic.
This theory is supported by epidemiologic and experimental evidence that has independently suggested roles for both granulocytes 169 and complement 170 in cardiovascular disease, an example of a set of diseases associated with increased circulating PGAs. 135 Additionally, an increase in alternative pathway activity, either through the addition of exogenous properdin (especially properdin tetramers) or competitive inhibition of Factor H-mediated cell-surface protection, sensitizes whole blood to robust PGA formation in the presence of low doses of the platelet agonist, TRAP. 156 The alternative pathway amplification loop can thus greatly exacerbate the response to mild thromboinflammatory stimuli when it overwhelms negative regulatory mechanisms. The consequence of inhibiting properdin in the presence of impaired Factor H cell-surface protection was discussed above for the PGA model, 156 and was also demonstrated in a different model by
Lesher et al.
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, who showed that inhibition of properdin in the presence of rH19-20 prevented lysis of human and murine erythrocytes by sera.
We have compared the inhibition of properdin to inhibition of C5 on sheep erythrocytes using the same rH19-20-mediated hemolysis assay as originally described, 24 and found properdin inhibitors to be approxi- by approximately 50%. 156 Given that the mechanism for the effect of properdin on TRAP-mediated PGA formation was related to its ability to increase C5a generation, these results were in agreement with findings from the studies by Harboe et al.
14 that showed the alternative pathway accounted for approximately 80% of terminal pathway activation when complement activity was initiated by either the classical or lectin pathway. 15 A clear example of a beneficial effect of inhibiting properdin in an in vivo disease model in which complement activity is not initiated by the alternative pathway comes from investigating the role of complement in a murine model of AAA. 99, 177 Not only did these studies show that properdin-deficient mice were resistant to AAA development, 99 a vascular inflammatory disease characterized by neutrophil infiltration, but it also showed that complement activity was initiated by lectin pathway-mediated activation following the deposition of anti-fibrinogen natural antibodies. 177 The fact that properdin inhibition was equally effective as lectin pathway inhibition in this model gives credence to the possibility that properdin inhibitors can have potent long-term effects in inflammatory vascular disorders, regardless of the mechanism by which complement activity is initiated.
While the ex vivo data support a role for properdin-enhanced generation of C5a, properdin inhibition would limit the generation of all complement effector molecules, and the potential in vivo effects of this should be considered. Decreased C3b and iC3b generation may limit neutrophil and monocyte infiltration into inflamed vasculature, 178, 179 while decreased C3a levels would limit vasodilatory and proinflammatory effects on the vasculature. C5a receptor antagonists could account for potential C5 cleavage by thrombin or other coagulation enzymes. 180, 181 To our knowledge, a therapeutic regimen such as this has never been tested in clinical trials.
With the rate of advances in understanding the roles of properdin and C5a in various disease models, these two types of inhibitors could be employed simultaneously in a way that potentially lowers the effective dose of each inhibitor, thus limiting potential side effects.
To date, no properdin inhibitors have been described that can specifically target different properdin oligomers. Given the enhanced functionality of properdin tetramers compared with other oligomers, 65, 156 inhibitors that specifically target properdin tetramers may be especially useful therapeutics. Development of such therapeutics would be challenging, since the properdin oligomers are identical except for the unique geometric constraints found at the vertices formed between two monomers. 54, 59 If novel inhibitors could be developed, howev- 
| Potential consequences of properdin inhibition
Despite potential effects of properdin inhibition on the generation of all complement effector molecules, the only documented consequence of properdin deficiency in humans is an increased susceptibility to Neisseria meningitidis meningitis and septicemia. Antibodies produced following vaccination with the available vaccines have largely prevented these life-threatening conditions. 183 Therefore, effective strategies to mitigate the only documented consequence of properdin deficiency in humans already exist.
In vivo mouse models have provided evidence for other potential consequences of systemic, long-term properdin inhibition. P −/− mice exhibited worsened colitis, associated with decreased infiltration of neutrophils into the intestine and corresponding increases in bacterial burden in an IL-10 −/− model of inflammatory bowel disease. 184 Properdin deficiency was also shown to be detrimental in a mouse model of infectious colitis utilizing Citrobacter rodentium. Increased pathogenesis in this model was related to an increase in infiltrating neutrophils and macrophages as a result of a decreased ability of intestinal epithelial cells to control initial bacterial burden, which was shown to be dependent on properdin-mediated generation of C5a. 185 While these studies both showed worsened outcomes with properdin deficiency, the detrimental effect of the absence of properdin was due to very different mechanisms in these complex diseases. These studies, thus, highlight the context-specific effects of properdin inhibition, which would not be universally applicable to all patients, in particular those that are normally properdin-sufficient, and could potentially be alleviated by careful clinical monitoring.
Steiner et al. 186 found a protective role for properdin in the development of early atherosclerotic lesions in male mice fed a low-fat diet, but this protective function was eliminated upon feeding mice a highfat diet. While these results are intriguing, due to the strict criteria for the protective effect of properdin (only male mice fed a low-fat diet), it is uncertain how properdin inhibition would affect the development of atherosclerosis, a complex inflammatory disease associated with multiple risk factors, in humans.
Properdin deficiency improved outcomes in a murine model of zymosan-induced non-septic shock, but exacerbated disease in LPSinduced non-septic shock. 107 This study serves as another example of context-specific roles for properdin that would need to be clinically monitored. It should be noted, however, that LPS is a potent neutrophil activator that induces full neutrophil degranulation. 187 Thus, transiently increased levels of properdin due to massive LPS-mediated neutrophil activation during non-septic shock may compensate for decreased properdin function due to properdin inhibitors in patients that are normally properdin sufficient.
| UNDERSTANDING THE INTERPLAY BETWEEN PROPERDIN AND FACTOR H IN THE MICROENVIRONMENT
Studies by Saggu et al. 31 and Blatt et al. 156 highlight the opposing roles of properdin and Factor H in the microenvironment. Aside from binding to key complement components in order to carry out their regulatory functions, both properdin and Factor H bind to a diverse set of ligands other than complement proteins. In addition to sulfatides and the polyanionic structures already mentioned, unfractionated properdin has recently been shown to bind to neutrophil myeloperoxidase, 87 Factor H-related protein-5 (CFHR-5) 81 ), and monomeric C-reactive protein (mCRP). 88 
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Factor H also binds to many of the same polyanions associated with properdin binding, including heparin, 50, [191] [192] [193] [194] [195] [196] [197] [198] heparan sulfate, 102, 193, 194, 196 and chondroitin sulfate C. 26, 199 Association with polyanions increases Factor H regulation on surfaces by directing it to specific cells 50, 193 and inducing oligomerization via the C-terminal domains. 200 156 and complement activation on human erythrocytes 49 when
Factor H regulation is impaired, could limit or prevent disease flareups resulting from alternative pathway activation that overwhelms the level of regulation provided by Factor H promoters.
| PROMOTING PROPERDIN ACTIVITY ON PATHOGENS
Much of this review has been dedicated to the potential utility of inhibiting properdin in thromboinflammatory diseases and the associated consequences; however, properdin undoubtedly is a key weapon in the fight against invading microorgansims. A murine model of polymicrobial sepsis showed increased morbidity and mortality in the presence of genetic properdin deficiency, 74 and properdin enhances complement activation on Chlamydia pneumoniae, 82 Neisseria meningitidis and gonorrhoeae, 93, 206 fungal glycans, 96 and Escherichia coli. 74, 89, 97 Therefore, finding ways to direct properdin activity to the microbial surface could provide novel ways to resolve infections.
Recombinantly produced properdin, predominantly containing non-physiological aggregates, enabled opsonization of Streptococcus pneumoniae and Neisseria meningitidis by human serum. In the case of Neisseria meningitidis, the recombinant properdin also mediated in vitro killing in serum. The injection of recombinant properdin was subsequently shown to have beneficial effects in murine infection models with both pathogens. 207 Spitzer et al. 89 showed that a single chain antibody (scFv) targeted to murine or human erythrocytes and linked to properdin could induce complement activation on the erythrocytes. Utilizing this targeting strategy against microorganisms could prove to be effective, especially if the scFv is directed against bacterial proteins known to bind complement regulatory proteins. For instance, Neisseria meningitidis expresses several proteins that recruit Factor H to its surface, [208] [209] [210] and thus scFv's directed against Factor H-binding proteins could promote alternative pathway activity on the bacteria by simultaneously increasing properdin activity and decreasing Factor H regulation. This strategy would also likely bypass any need for antibody-dependent classical pathway initiation due to the potent complement initiation properties of scFv-properdin. 89 Many bacteria other than Neisseria species including Borrelia burgdorferi, 211 Yersinia enterocolitica, 212 and Streptococcus pyogenes 213 bind Factor H (reviewed in 16) to protect themselves from the alternative pathway, therefore scFv-properdin targeted against Factor H-binding proteins could be an efficient strategy for treating infections resulting from a diverse array of pathogens.
| CONCLUDING REMARKS
Properdin is a powerful inflammatory modulator that is tightly regu- for the interplay between properdin and Factor H, we will better be able to predict the potential effects of either inhibiting or promoting properdin activity and could develop strategies to maximize effects on the alternative pathway by employing methods that simultaneously inhibit properdin and promote Factor H activity, or vice versa. These types of strategies may find particular usefulness in the clinic to limit inflammation in diseases marked by excessive alternative pathway activation or to treat microbial infections. With these thoughts in mind, we can collectively contribute to the knowledge required to make significant advances in the treatment or prevention of multiple disease etiologies.
